Vontobel Holding Ltd. Cuts Position in United Therapeutics Co. (NASDAQ:UTHR)

Vontobel Holding Ltd. cut its stake in United Therapeutics Co. (NASDAQ:UTHR) by 18.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,355 shares of the biotechnology company’s stock after selling 309 shares during the period. Vontobel Holding Ltd.’s holdings in United Therapeutics were worth $478,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in UTHR. Louisiana State Employees Retirement System raised its stake in shares of United Therapeutics by 0.8% during the fourth quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the biotechnology company’s stock valued at $4,375,000 after acquiring an additional 100 shares during the last quarter. JSF Financial LLC grew its position in United Therapeutics by 4.0% in the 4th quarter. JSF Financial LLC now owns 2,996 shares of the biotechnology company’s stock worth $1,057,000 after purchasing an additional 114 shares during the period. Savant Capital LLC grew its position in United Therapeutics by 2.7% in the 4th quarter. Savant Capital LLC now owns 10,205 shares of the biotechnology company’s stock worth $3,601,000 after purchasing an additional 266 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics during the 4th quarter worth $25,000. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its stake in shares of United Therapeutics by 6,925.0% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,100 shares of the biotechnology company’s stock worth $9,904,000 after acquiring an additional 27,700 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

UTHR opened at $367.36 on Friday. The firm has a 50 day moving average price of $362.70 and a 200 day moving average price of $359.94. The company has a market cap of $16.40 billion, a PE ratio of 16.13, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $214.52 and a 1 year high of $417.82.

Analysts Set New Price Targets

A number of research analysts recently weighed in on UTHR shares. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Finally, StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $382.08.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $355.77, for a total transaction of $90,721.35. Following the completion of the sale, the director now owns 5,528 shares in the company, valued at approximately $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 124,164 shares of company stock valued at $45,398,793 over the last 90 days. 11.90% of the stock is owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.